| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | -0.21 | 2e-06 |
| mRNA | AZD0530 | CCLE | pan-cancer | AAC | -0.19 | 8e-05 |
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | -0.22 | 0.0001 |
| mRNA | decitabine | CTRPv2 | pan-cancer | AAC | -0.11 | 0.0002 |
| mRNA | lapatinib | CCLE | pan-cancer | AAC | -0.16 | 0.0003 |
| mRNA | Cytarabine | CTRPv2 | pan-cancer | AAC | -0.1 | 0.0003 |
| mRNA | Bexarotene | CTRPv2 | pan-cancer | AAC | 0.13 | 0.0003 |
| mRNA | Rapamycin | gCSI | pan-cancer | AAC | -0.2 | 0.0003 |
| mRNA | lapatinib | gCSI | pan-cancer | AAC | -0.19 | 0.0005 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | -0.15 | 0.0009 |